IDEAYA Biosciences presents a high-risk, high-reward opportunity driven by its synthetic lethality pipeline, but its financial profile is characterized by extreme volatility tied to one-time collaboration milestones. The $207.8M revenue spike in 2025Q3, which ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$1.22-15.1% vs -$1.06 | $9M+10.4% vs $8M |
Q2 2026 May 5, 2026 | -$1.11-3.7% vs -$1.07 | $7M+30.2% vs $5M |
Q1 2026 Feb 17, 2026 | -$0.94+1.2% vs -$0.95 | $11M+72.5% vs $6M |
Q4 2025 Nov 4, 2025 | $1.33+240.6% vs -$0.95 | $208M+3395.1% vs $6M |
Squarepoint Ops LLC reduced its holdings in IDEAYA Biosciences, Inc. (NASDAQ: IDYA) by 74.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,218 shares of the company's stock after selling 74,060 shares during the period. Squarepoint Ops LLC's holdings in IDEAYA
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of darovasertib across the uveal melanoma patient journey into the adjuvant setting, where there is a significant unmet need for systemic treatment options designed to reduce the risk of metastatic recurrence SOUTH SAN FRANCISCO, Calif., Sept. 9, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed local therapy and have an increased risk of developing metastatic disease.
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
Benchmark IDYA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for IDEAYA Biosciences, Inc. (IDYA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.46 | $3.29B | -29.27 | 3024.43% | -51.99% | -10.92% | — | |
| $4.92 | $199.75M | 4.03 | 55.25% | 45.97% | 10.97% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — |
IDEAYA Biosciences, Inc. (IDYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
IDEAYA Biosciences, Inc. (IDYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
May 5, 2026·SEC
May 5, 2026·SEC
Get notified when IDYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IDEAYA Biosciences, Inc. (IDYA) stock FAQ — growth, dividends, profitability & financials explained
IDEAYA Biosciences, Inc. (IDYA) reported $234.1M in revenue for fiscal year 2025.
IDEAYA Biosciences, Inc. (IDYA) grew revenue by 3024.4% over the past year. This is strong growth.
IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $175.0M for fiscal year 2025.
IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -10.9%. Negative ROE indicates the company is unprofitable.
IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $190.0M in fiscal year 2025, likely due to heavy capital investments.
